Indian Biogenerics: An Evolving Industry - Indian biogenerics could form a major piece of the global biotherapeutics market in the future. - BioPharm International


Indian Biogenerics: An Evolving Industry
Indian biogenerics could form a major piece of the global biotherapeutics market in the future.

BioPharm International
Volume 21, Issue 2


Table 1. Biotherapeutics in India and their manufacturers
India's biogenerics industry remains relatively small, and nearly all of the products marketed now or in the near future are accounted for by a handful of companies (Tables 1 and 2). There are four main players.

Table 2. Top biotech organizations in india by revenue
Biocon: India's first and largest biotech company was founded in 1978. Bangalore-based Biocon is now the largest biotech firm in Asia by market capitalization and the sixteenth largest worldwide. Biocon's existing biogenerics product line includes recombinant human insulin (Insugen), EPO (Erypro), G-CSF, and streptokinase. Most of Biocon's pipeline is now filled with innovative molecules, and it already markets a novel biologic, an anti-epidermal growth factor receptor (EGFR) MAb (BioMAB-EGFR) for head and neck cancers. As Biocon's CEO, Kiran Mazumdar-Shaw, told Fortune a year ago, "Unfortunately, [analysts] still tend to categorize us as a generics company...We keep saying, 'Look, we're not interested in generic companies, because we're trying not to be one.'"4

Dr. Reddy's Laboratories: India's third largest pharmaceuticals company, Dr. Reddy's was founded in 1984 in Hyderabad as a bulk pharmaceuticals manufacturer and soon grew to become one of India's best known generics makers. Among other ventures, Dr. Reddy's has manufacturing plants in the UK and a research facility in the US. The company currently markets only two biologics, both generics: Reditux, a version of Roche's blockbuster rituximab monoclonal against non-Hodgkins lymphoma; and Grafeel, a version of G-CSF. Dr. Reddy's announced in mid-2007 that it planned to invest $20 million to expand its biogenerics capability, and expected to roll out one new biogeneric product per year for the next eight years.5

Ranbaxy Laboratories/Zenotech: Founded in 1961, Haryana-based Ranbaxy is India's largest pharmaceutical company. It recently decided to move toward biogenerics by taking a large stake in Hyderabad-based Zenotech, an established biotech firm. The two companies now sell biogeneric versions of G-CSF and GM-CSF and have an Interleukin-2 generic, a recombinant HGH generic and a rituximab generic in clinical trials.

Shantha Biotechnics: Hyderabad-based Shantha, now 60% owned by Merieux Alliance, currently markets three biogenerics—an interferon alpha-2b, a streptokinase, and an EPO. The company's biogenerics pipeline includes a tPA product and a pegylated interferon for treating hepatitis C, although most of Shantha's research and development has been focused on new biologics and vaccines. Shantha has been making a recombinant-protein hepatitis-B vaccine since 1997.

Wockhardt: Based in Mumbai, Wockhardt currently has six biogenerics on the market in India: an EPO and a recombinant human insulin. Its pipeline includes an insulin glargine generic, interferon alpha 2b, and G-CSF.


New regulatory guidelines enable a streamlined clinical trials and review process under a single National Biotechnology Regulatory Authority.6 However, India's biogenerics manufacturers are less interested in India's market, or in other loosely regulated markets where consumers are relatively poor, than they are in the wealthy US and European markets.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here